Lapsed Sep 30, 2026 on the fee record · Medium confidence
20-year base term ends Dec 16, 2031
Why Medium: A parent in the chain could not be resolved.
Third maintenance fee unpaid; grace period ended.
Held by Sunovion Pharmaceuticals Inc.
Filed Apr 8, 2013 as application 13/858,638 · Granted Sep 30, 2014
Base term, 20 years from filing
Today
Lapsed Sep 30, 2026
2011
2031
Clock starts
Dec 16, 2011
Dec 16, 2011
No longer in force
Sep 30, 2026
Sep 30, 2026
Granted
Sep 30, 2014
Sep 30, 2014
Term would have run to
Dec 16, 2031
Dec 16, 2031
base term
after the term ends
fee events
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
None
Terminal disclaimer
No disclaimer on this record.
2 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
7
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
Its term would have run to Dec 16, 2031: its 20-year base term, with no adjustment for prosecution delay. Confidence: Medium. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Dec 16, 2011, when application PCT/US2011/065665, the earliest non-provisional in its chain, was filed (this one was filed Apr 8, 2013); a parent in its chain could not be resolved (the next row) | Dec 16, 2031 | High confidence |
| Continuity chain | A parent in the chain could not be resolved | dated from this application's own claim | Medium confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | None on record | no cap applied | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 2 of 3 maintenance fees paid | lapsed Sep 30, 2026 | High confidence |
| Computed term end | The steps above, in order | Sep 30, 2026 | Medium confidence |
This family
| Application PCT/US2011/065665 | PCT application no patent term | no patent term |
| US 8,414,922 | Lapsed on the fee record Apr 2025 | Apr 2025 |
| US 8,846,074 | this patent Sep 2026 | Sep 2026 |
| US 9,283,219 | In force no later than Dec 2031 | no later than Dec 2031 |
| US 9,427,412 | Lapsed on the fee record Aug 2024 | Aug 2024 |
| US 10,285,953 | In force no later than Dec 2031 | no later than Dec 2031 |
| US 11,419,769 | Lapsed on the fee record Aug 2026 | Aug 2026 |
The applications whose file history this site holds. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Aug 29, 2014 Reel 33642, frame 58 | Bryson, Nathan John; Giovinazzo, Anthony John | Cynapsus Therapeutics, Inc. | Assignment of Assignor's Interest |
| Mar 23, 2015 Reel 35230, frame 355 | Arx, LLC | Cynapsus Therapeutics, Inc. | Assignment of Assignor's Interest |
| Jul 20, 2016 Reel 39199, frame 639 | Barnhart, Scott David; Koons, Michael Clinton | Arx, LLC | Assignment of Assignor's Interest |
| Nov 10, 2016 Reel 40277, frame 773 | Sunovion CNS Development Canada ULC | Sunovion Pharmaceuticals Inc. | Assignment of Assignor's Interest |
| Nov 10, 2016 Reel 40587, frame 262 | Cynapsus Therapeutics Inc. | Project Pegasus Sub Acquisition ULC | Assignment of Assignor's Interest |
| Nov 10, 2016 Reel 40588, frame 155 | Project Pegasus Sub Acquisition ULC | Sunovion CNS Development Canada ULC | Merger |
| Dec 15, 2016 Reel 40940, frame 603 | Sunovion CNS Development Canada ULC | Sunovion Pharmaceuticals Inc. | Corrective Assignment to Correct the Effective Date of Assignment Previously Recorded at Reel: 040277 Frame: 0773. Assignor(S) Hereby Confirms the Assignment. |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
Citations
47
later US patents cite this one
That is top 25% of utility patents granted in 2014 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.